THERAPEUTICS
Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder
| The first 150 words of the full text of this article appear below. |
How effective and safe is aripiprazole as an adjunctive treatment for major depressive disorder (MDD) in people who have failed to respond to one or more antidepressants?
381 adult outpatients (aged 18–65 years) with a DSM-IV diagnosis of MDD, who had inadequate response to an 8–week single blind antidepressant trial, and had previously experienced inadequate response to between one and three antidepressants (assessed using the Antidepressant Treatment Response Questionnaire). See online notes for details.
36 sites in the USA; September 2004 to December 2006.
Adjunctive aripiprazole (starting dose 5 mg/day, which could be adjusted to a maximum of 20 mg/day as tolerated by week 4) or placebo for 6 weeks. Type of antidepressant or dosage was not changed during this period.
Change in symptoms from baseline (Montgomery-Åsberg Depression Rating Scale (MADRS)); adverse events.
85% completed treatment (97% analysed for efficacy using last observation carried forward).
Design: Randomised controlled trial.
Allocation:
Reader in Affective Disorders, Institute of Psychiatry, King's College London, London, UK
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
